Joint development of catheter-based cell transplantation therapy
First written in FY2023. 9 of 13 entries say "Advanced", first in FY2024-Q1. Latest entry: 2026-09-11.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In our joint research and development with ASAHI INTECC CO.,LTD., research and development on the catheter and the cells to be administered has progressed smoothly, and we established proof of concept in small animals. We are currently conducting large-animal experiments toward establishing proof of concept in large animals, while preparing for a PMDA application and advancing expansion into the United States.」
The company established proof of concept in small animals and moved to the stage of establishing proof of concept in large animals, preparing the PMDA application and expanding into the United States. - FY2024RestatedAnnual report
「In our joint research and development with ASAHI INTECC CO.,LTD., research and development on the catheter and the cells to be administered has progressed smoothly, and we are conducting experiments using large animals. We also agreed to conduct closer joint research and development, promote consideration of commercialization in Japan and the United States, and discuss applications to treatments for organs other than the heart.」
The joint development policy, including large-animal experiments, consideration of commercialization in Japan and the United States, and applications to other organs, continued. - FY2024-Q3RestatedAnnual report
「During the cumulative third-quarter period under review, our joint research and development with ASAHI INTECC CO.,LTD. progressed smoothly. We therefore reached an additional agreement to conduct closer joint research and development, promote consideration of commercialization in Japan and the United States, and discuss applications to treatments for organs other than the heart.」
The additional agreement covering commercialization in Japan and the United States and applications to other organs was reiterated. No new expansion beyond the previous quarter’s plan was reported. - FY2024-Q2RaisedAnnual report
「In response to the smooth progress of research and development on the catheter and the cells to be administered, we reached an additional agreement with ASAHI INTECC CO.,LTD. to conduct closer joint research and development, promote consideration of commercialization in Japan and the United States, and discuss applications to treatments for organs other than the heart.」
The additional agreement explicitly expanded the geographic scope to Japan and the United States and the application scope to organs other than the heart. - FY2024-Q1AdvancedAnnual report
「During the cumulative first-quarter period under review, we developed cells to be administered through a catheter and confirmed pharmacological efficacy in a nonclinical study using small animals. In the joint research with ASAHI INTECC CO.,LTD., we are conducting nonclinical studies using large animals.」
Pharmacological efficacy of catheter-administered cells was confirmed in a small-animal nonclinical study, while the joint research proceeded to large-animal nonclinical studies. - FY2023First statedAnnual report
「As a pipeline for mild heart disease, we are jointly developing with ASAHI INTECC CO.,LTD. a treatment technology for transplanting human iPS cell-derived cells into the heart through a new intravascular approach using a catheter.」
A catheter prototype has been manufactured. The company is proceeding with improvements based on specialist feedback, large-animal studies, preliminary consultation with PMDA, and clinical-trial protocol design.